Stock data
| Market cap. | US$10.7m |
| Last close | US$1.58 |
| High / Low (52 weeks) | US$1.8 / US$1.4 |
| Stock market listing | US |
| Forecast net debt (US$m) | 0.9 |
| Forecast gearing ratio (%) | 27 |
| Team | Healthcare |
| Sector | Pharmaceutical & healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | 3.9 | 1.9 | (0.6) |
| Relative * | 6.9 | 11.1 | (0.1) |
* % Relative to local index
Other companies in sector Show
Company news
INTERNATIONAL STEM CELL CORPORATION (OTCMKTS:ISCO) Files An 8-K Entry into a ...Thu, 17 May 2018 09:00:00 GMT |
International Stem Cell Corp.Mon, 09 Oct 2017 12:32:09 GMT |
International Stem Cell Corporation Announces Positive Interim Clinical ...Mon, 13 Nov 2017 13:30:00 GMT |
International Stem Cell Corporation Treated Real Estate Icon Kevin WeeksThu, 11 Jan 2018 13:41:15 GMT |
Is International Stem Cell Corporation Finally Starting To Move Clinical ...Thu, 31 Dec 2015 01:13:43 GMT |
| Y/E Dec | Revenue (US$m) | EBITDA (US$m) | PBT (US$m) | EPS (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2016A | 7.2 | (4.5) | (4.9) | (152.07) | N/A | N/A |
| 2017A | 7.5 | (4.6) | (4.9) | (118.86) | N/A | N/A |
| 2018E | 11.5 | (2.8) | (3.2) | (50.00) | N/A | N/A |
| 2019E | 13.5 | (5.9) | (7.0) | (104.69) | N/A | N/A |
Last updated on 04/12/2018
Latest research
Strong biomedical sales and new clinical data
Update | Pharmaceutical & healthcare | 04/12/2018
Biomedical sales more than double
Update | Pharmaceutical & healthcare | 20/08/2018
Third cohort ready to go
Update | Pharmaceutical & healthcare | 06/06/2018
Moving forward in Parkinsons and TBI
Outlook | Pharmaceutical & healthcare | 14/05/2018
Interim Parkinson's data
Update | Pharmaceutical & healthcare | 03/01/2018
Green light for second cohort
Update | Pharmaceutical & healthcare | 24/05/2017
Dosing of first cohort complete
Update | Pharmaceutical & healthcare | 27/04/2017
Phase I progressing
Update | Pharmaceutical & healthcare | 14/12/2016
First patient dosed in Phase I trial
Update | Pharmaceutical & healthcare | 02/08/2016
Seeking a better treatment for Parkinson's
Initiation | Pharmaceutical & healthcare | 16/05/2016
Investment summary
International Stem Cell (ISCO) reported Q318 revenues of $3.2m, up 73.0% compared to Q317 mainly due to the biomedical business, which had quarterly revenues of $2.8m, up 112.8% year-on-year. Additionally, the company reported updated data from the Phase I trial of ISC-hpNSC in Parkinson’s disease (PD). At the six-month time point, the percentage OFF-Time, a key endpoint for PD treatment, decreased an average of 49% for the second cohort of patients, compared to 24% for the first, with four patients in each cohort.
Last updated on 04/12/2018
Industry outlook
ISCO’s technology platform is based on human parthenogenetic stem cells (hpSCs). Parthenogenetic stem cells are created from unfertilized human eggs (oocytes) chemically activated to make the cells pluripotent. As hpSCs express fewer parental histocompatibility antigens, they reduce the risk of immune rejection
Last updated on 29/11/2018
Key management
| Andrey Semechkin, CEO and Co-Chairman |
| Donald Wright, Co-Chairman |
| Jennifer Stephens, Acting CFO |
| Russell Kern, Executive Vice President, CSO |
Company address
| 5950 Priestly Drive Carlsbad CA 92008 United States +1 760 940 6383 View website |